DEVELOPMENTAL FUNDS (Core-002)

$200,000P30FY2015CANIH

Icahn School Of Medicine At Mount Sinai, New York NY

Investigators

Linked publications & trials

Paper 39763802 Paper 39542655 Paper 39478230 Paper 39454027 Paper 39388279 Paper 39384951 Paper 39378878 Paper 39378840 Paper 39283238 Paper 39282294 Paper 39229151 Paper 39222793 Paper 39106432 Paper 39037651 Paper 39010877 Paper 38968143 Paper 38937606 Paper 38934093 Paper 38888723 Paper 38885804 Paper 38870008 Paper 38867022 Paper 38866556 Paper 38866555 Paper 38834239 Paper 38798338 Paper 38783890 Paper 38782828 Paper 38744503 Paper 38630441 Paper 38609316 Paper 38602846 Paper 38508241 Paper 38464025 Paper 38457262 Paper 38456551 Paper 38431550 Paper 38430535 Paper 38405698 Paper 38373106 Paper 38339227 Paper 38319712 Paper 38311543 Paper 38277235 Paper 38242983 Paper 38230434 Paper 38184712 Paper 38162407 Paper 38143925 Paper 38134932 Paper 38134422 Paper 38117900 Paper 38082068 Paper 38076914 Paper 38060380 Paper 38057662 Paper 38014330 Paper 38014085 Paper 37982987 Paper 37982738 Paper 37914840 Paper 37905126 Paper 37884500 Paper 37772981 Paper 37756380 Paper 37732256 Paper 37728489 Paper 37676642 Paper 37624910 Paper 37608772 Paper 37607770 Paper 37605008 Paper 37550577 Paper 37537299 Paper 37451265 Paper 37439808 Paper 37409267 Paper 37382635 Paper 37267517 Paper 37231268 Paper 37210723 Paper 37156770 Paper 37155979 Paper 37144982 Paper 37142257 Paper 37086018 Paper 37081148 Paper 37069249 Paper 37067914 Paper 36919946 Paper 36900251 Paper 36823213 Paper 36813963 Paper 36802311 Paper 36706355 Paper 36702834 Paper 36690614 Paper 36638361 Paper 36634824 Paper 36628884

Abstract

ABSTRACT ? DEVELOPMENTAL FUNDS The mission of the Tisch Cancer Institute is to advance the field of cancer research, treatment and prevention and to facilitate the availability of these advancements to our communities so as to extend and improve the lives of cancer patients and their families. In order to achieve this mission, the TCI strategic plan includes specific objectives and goals that guide the use of Development Funds. In order to facilitate inter-programmatic and translational research in the TCI, senior leadership made a commitment to support pilot projects that bring together laboratory, clinical and population science investigators. As such, priority is given to research teams that represent transdisciplinary and inter- programmatic collaborations. Similarly, the TCI Director and senior leadership felt strongly that additional funds should be identified to help nurture and develop promising young cancer investigators. This strategic goal led to the establishment of Young Cancer Scientists Awards. TCI Developmental Funds are also used to initiate and grow research facilities that are seen as critical for promoting the progress of TCI research programs. Over the past 3 years, the TCI has allocated funds for the development of both a Human Immune Monitoring Center (HIMC) and a Hematological Malignancies Tissue Bank (HMTB), services that the TCI External Advisory Board had highly recommended during their 2010 and 2011 site visits. Furthermore, because enhancing access to solid tumor specimens is seen as a top priority by program leaders, internal strategic committees and the EAB, the TCI has provided funds to support the expansion of the Biorepository and Pathology Services. Most recently, the TCI has initiated the development of a Vaccine and Cell Therapy Facility, which represents another critical service for research in cancer immunotherapies and will function synergistically with the Human Immune Monitoring Center.

View original record on NIH RePORTER →